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BACKGROUND
We previously reported prolonged progression-free survival and marginally prolonged 
overall survival among postmenopausal patients with hormone receptor–positive 
metastatic breast cancer who had been randomly assigned to receive the aromatase 
inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, 
as compared with anastrozole alone, as first-line therapy. We now report final sur-
vival outcomes.
METHODS
We randomly assigned patients to receive either anastrozole or fulvestrant plus 
anastrozole. Randomization was stratified according to adjuvant tamoxifen use. 
Analysis of survival was performed by means of two-sided stratified log-rank tests and 
Cox regression. Efficacy and safety were compared between the two groups, both 
overall and in subgroups.
RESULTS
Of 707 patients who had undergone randomization, 694 had data available for analysis. 
The combination-therapy group had 247 deaths among 349 women (71%) and a me-
dian overall survival of 49.8 months, as compared with 261 deaths among 345 women 
(76%) and a median overall survival of 42.0 months in the anastrozole-alone group, a 
significant difference (hazard ratio for death, 0.82; 95% confidence interval [CI], 
0.69 to 0.98; P = 0.03 by the log-rank test). In a subgroup analysis of the two strata, 
overall survival among women who had not received tamoxifen previously was longer 
with the combination therapy than with anastrozole alone (median, 52.2 months and 
40.3 months, respectively; hazard ratio, 0.73; 95% CI, 0.58 to 0.92); among women 
who had received tamoxifen previously, overall survival was similar in the two groups 
(median, 48.2 months and 43.5 months, respectively; hazard ratio, 0.97; 95% CI, 
0.74 to 1.27) (P = 0.09 for interaction). The incidence of long-term toxic effects of 
grade 3 to 5 was similar in the two groups. Approximately 45% of the patients in 
the anastrozole-alone group crossed over to receive fulvestrant.
CONCLUSIONS
The addition of fulvestrant to anastrozole was associated with increased long-term 
survival as compared with anastrozole alone, despite substantial crossover to fulves-
trant after progression during therapy with anastrozole alone. The results suggest 
that the benefit was particularly notable in patients without previous exposure to ad-
juvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; 
ClinicalTrials.gov number, NCT00075764.)
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Metastatic hormone-receptor–pos-itive breast cancer is considered to be incurable. Although some patients have 
many years of disease control with a third-gen-
eration aromatase inhibitor such as anastrozole, 
the median survival is only 41.3 months.1
We hypothesized that adding the selective 
estrogen-receptor down-regulator fulvestrant to 
anastrozole therapy would be more effective than 
treatment with anastrozole alone, given that one 
of the resistance mechanisms to anastrozole is 
chronic stimulation of estrogen receptors by low 
levels of estradiol. As we previously reported, the 
combination of fulvestrant and anastrozole pro-
longed progression-free survival (median, 15.0 
months with the combination therapy vs. 13.5 
months with anastrozole alone; hazard ratio for 
progression or death, 0.80; P = 0.007) in a prospec-
tive, randomized clinical trial (S0226).1 The inci-
dence of severe toxic effects was similar in the 
two groups, and almost all the patients were able 
to receive treatment. Furthermore, at a median 
follow-up of 3 years, we observed that the median 
overall survival was 47.7 months with the combi-
nation therapy and 41.3 months with anastrozole 
alone (hazard ratio, 0.81; 95% confidence interval 
[CI], 0.65 to 1.00; P = 0.05).1 We now report updated 
trial outcomes at a median follow-up of 7 years 
in patients who did not have disease progression, 
and we discuss the effect of combination therapy 
(anastrozole plus fulvestrant) as compared with 
anastrozole alone on overall survival in various 
subgroups defined on the basis of clinical char-
acteristics.
Me thods
Trial Oversight
We conducted this investigator-initiated, multi-
center, randomized, open-label trial (S0226) to 
compare the efficacy of the addition of fulvestrant 
to anastrozole therapy with that of anastrozole 
therapy alone (followed by use of fulvestrant in 
patients who were not in visceral crisis) in patients 
with metastatic breast cancer. The trial was de-
signed and conducted, and the data were analyzed, 
by the Southwest Oncology Group Cooperative 
Group, which was funded by the National Can-
cer Institute (NCI), with review and collaboration 
from the National Cancer Institute of Canada and 
the NCI Cancer Therapy Evaluation Program. The 
first two authors assume full responsibility for 
the accuracy and completeness of the data and 
vouch for the data analysis and for the fidelity of 
the trial to the protocol (available with the full text 
of this article at NEJM.org). All the drafts of the 
manuscript were prepared and approved by all the 
authors. The trial data were reviewed by a data 
and safety monitoring committee every 6 months.
AstraZeneca provided the trial medications at 
no cost to the enrolled patients. AstraZeneca pro-
vided comments on an early draft of the manu-
script but contractually was not allowed to ap-
prove or disapprove of the submission of the 
manuscript for publication. AstraZeneca was not 
provided with the trial data and did not partici-
pate in the statistical analysis. The statistical 
analysis plan is available with the protocol.
Patients
The trial design and the characteristics of the pa-
tients at baseline have been published previously.1 
The trial enrolled postmenopausal women with 
estrogen-receptor–positive or progesterone-recep-
tor–positive metastatic breast cancer who had a 
Zubrod’s performance-status score of 0 to 2 (on a 
scale of 0 to 5, with higher scores indicating 
greater disability; a score of 0 indicates that the 
patient is fully active, 1 that the patient is re-
stricted in strenuous activity but is ambulatory, 
and 2 that the patient is unable to work but is 
ambulatory and capable of self-care and up and 
about >50% of waking hours). No previous chemo-
therapy, hormonal therapy, or immunotherapy for 
metastatic disease was allowed. Previous treat-
ment with adjuvant tamoxifen was allowed and 
was a stratification factor. Neoadjuvant or adju-
vant chemotherapy or aromatase inhibitor thera-
py had to be completed more than 12 months 
before enrollment.
We randomly assigned patients in a 1:1 ratio to 
receive standard-dose anastrozole alone or anas-
trozole plus fulvestrant. Fulvestrant was admin-
istered at a loading dose of 500 mg on day 1, 
with 250 mg administered on days 14 and 28 and 
then 250 mg administered as maintenance therapy 
every 28 days. At the time of progression, in the 
absence of visceral crisis, crossover to fulvestrant 
was strongly encouraged. Near the end of the trial, 
a loading dose followed by an increased mainte-
nance dose of fulvestrant of 500 mg per month 
was shown to be more effective than 250 mg per 
month, and patients were permitted this dose 
thereafter if they had disease progression.2 The 
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enrollment goal was 690 eligible patients equally 
assigned to each of the two groups, with random-
ization stratified according to adjuvant tamoxi-
fen use.
Statistical Analysis
The primary end point was progression-free sur-
vival, which was defined as the time from random-
ization to progression or death from any cause. 
Secondary end points included overall survival and 
safety. The primary statistical analysis was an 
intention-to-treat analysis that used stratified log-
rank tests, followed by Cox regression to estimate 
the hazard ratio and 95% confidence interval.
The trial had 90% power at a two-sided alpha 
level of 0.05 to detect hazard ratios consistent with 
an expected median progression-free survival of 
10 months in the monotherapy group, as com-
pared with 13 months in the combination-therapy 
group, and with an expected median overall sur-
vival of 36 months and 48 months, respectively. 
Subgroup comparisons were conducted within the 
prespecified stratification factor (adjuvant tamox-
ifen therapy). Post hoc subgroup analyses were 
also conducted. There was no prespecified plan 
for adjustment for multiple comparisons. P values 
are reported for comparisons between the two in-
tervention groups for the analyses of progression-
free survival and overall survival. For the other 
analyses, point estimates and 95% confidence in-
tervals are reported. The confidence intervals were 
not adjusted for multiple comparisons, and infer-
ences drawn from them may not be reproducible.
R esult s
Patients
A total of 707 patients underwent randomization 
from June 2004 through June 2009 (Fig. 1). A total 
of 13 patients were excluded (12 ineligible patients 
and 1 who withdrew consent), leaving 694 pa-
tients who had data that could be analyzed.1 The 
median age of the patients was 65 years; 40% of 
the patients had received adjuvant tamoxifen pre-
viously, and 33% had received adjuvant chemo-
therapy previously. A total of 8% of the patients 
in the anastrozole-alone group and 10% of those 
in the combination-therapy group had cancer that 
was positive for human epidermal growth factor 
receptor 2 (HER2). Further information regarding 
the characteristics of the patients and their dis-
ease at baseline has been reported previously.1
In the group that received anastrozole alone, 
45% of the patients crossed over to receive fulves-
trant (including at least 5 patients who received 
the 500-mg maintenance dose) at the time of pro-
gression. At least 9 of 349 patients in the combi-
nation-therapy group began receiving the 500-mg 
maintenance dose after progression (after Feb-
ruary 2011, because of the approval of the higher-
dose fulvestrant therapy by the Food and Drug 
Administration). (Because centers were not re-
quired to report switching from 250 mg to 500 mg, 
these numbers are underestimates.)
Updated Number of Events
In the additional 5 years of follow-up from the 
original report to the present report, the number 
of events of disease progression or death increased 
from 565 to 647, but the hazard ratios changed 
only slightly. The number of deaths increased from 
330 to 508, but again the hazard ratios were 
little changed. Because of more deaths and thus 
improved power, the estimated hazard ratio be-
came more certain, with a P value changing from 
0.05 to 0.03, and allowed for the estimation of 
5-year survival rates.
Progression-free Survival
Updated outcomes regarding progression-free sur-
vival are presented in Figure 2. There were 647 
events of disease progression or death (329 events 
in the anastrozole-alone group and 318 in the 
combination-therapy group) among 694 eligible 
patients (345 and 349 patients, respectively). The 
median follow-up among the patients who did 
not have disease progression was 7 years, with a 
maximum of 12 years. Overall, the median pro-
gression-free survival was 13.5 months in the an-
astrozole-alone group and 15.0 months in the 
combination-therapy group (hazard ratio for pro-
gression or death, 0.81; 95% CI, 0.69 to 0.94; 
stratified P = 0.007 by the log-rank test). In a sub-
group analysis of the two strata, among women 
who had not received tamoxifen previously (414 
[60%]), the median progression-free survival was 
12.7 months in the anastrozole-alone group, as 
compared with 16.7 months in the combination-
therapy group (hazard ratio, 0.73; 95% CI, 0.60 
to 0.89); among women with previous exposure to 
adjuvant tamoxifen (280 [40%]), the median pro-
gression-free survival was similar in the two 
groups (13.9 months and 13.6 months, respec-
tively; hazard ratio, 0.93; 95% CI, 0.73 to 1.19).
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Overall Survival
Table 1 and Figure 3 show the final outcomes re-
garding overall survival. Prolonged overall survival 
was seen in the group that received combination 
therapy: the median overall survival was 42.0 
months in the anastrozole-alone group and 49.8 
months in the combination-therapy group, on the 
basis of 261 and 247 deaths, respectively. The dif-
ference between the survival curves was signifi-
cant (hazard ratio, 0.82; 95% CI, 0.69 to 0.98; 
P = 0.03 by the log-rank test).
In a subgroup analysis involving women who 
had not received tamoxifen previously, the median 
overall survival was 40.3 months in the anastro-
zole-alone group, as compared with 52.2 months 
in the combination-therapy group (hazard ratio, 
0.73; 95% CI, 0.58 to 0.92); among women with 
previous exposure to adjuvant tamoxifen, the me-
dian overall survival was 43.5 months and 48.2 
months, respectively (hazard ratio, 0.97; 95% CI, 
0.74 to 1.27) (P = 0.09 for interaction). Patients in 
the group that received anastrozole alone who 
crossed over had postprogression survival that 
was similar to that among patients who received 
combination therapy (results not significant; data 
not shown).
Post Hoc Subgroup Analyses
Additional post hoc subgroup analysis was per-
formed to evaluate overall survival (Fig. 4). None 
of the P values for interaction were significant in 
any of the subgroup analyses. Patients who had 
been treated with tamoxifen were categorized ac-
cording to whether there had been more than 6.5 
years between the first diagnosis and trial enroll-
ment or randomization or 6.5 years or less. The 
former group was combined with the population 
of patients who had not received endocrine therapy 
previously, and this population was designated 
as the endocrine-sensitive population; in contrast, 
Figure 1. Enrollment, Randomization, and Follow-up of the Patients.
695 Were eligible
707 Patients underwent randomization
12 Were excluded
9 Did not have metastatic disease
1 Underwent chemotherapy previously
1 Was estrogen-receptor– and
progesterone-receptor–negative
1 Did not undergo chest imaging
345 Were assigned to receive anastrozole
341 Received anastrozole
4 Did not receive anastrozole
350 Were assigned to receive combination
therapy with anastrozole and fulvestrant
348 Received combination therapy
2 Did not receive combination therapy
345 Were included in follow-up
7 Did not have progression
9 Had last assessment ≥18 mo ago
329 Had disease progression or died
261 Died
350 Were included in follow-up
1 Withdrew consent
13 Did not have progression
18 Had last assessment ≥18 mo ago
318 Had disease progression or died
247 Died
345 Were included in the analysis 349 Were included in the analysis
1 Who had withdrawn consent was excluded
from the analysis
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the latter group was designated as the endocrine-
refractory (acquired endocrine resistance) popu-
lation. The cutoff point of 6.5 years was chosen 
to allow for 6 months of adjuvant chemotherapy, 
5 years of adjuvant tamoxifen therapy, and a final 
1-year tamoxifen-free period before relapse, giv-
en the standard definitions of endocrine-sensi-
tive disease and endocrine-refractory disease.
A total of 9% of the patients in the anastro-
zole-alone group and 12% in the combination-
therapy group had disease that was resistant to 
endocrine therapy. In the endocrine-sensitive 
population, the median overall survival was 42.3 
months (95% CI, 38.9 to 47.8) in the anastrozole-
alone group and 50.7 months (95% CI, 46.6 to 
58.3) in the combination-therapy group; in the 
endocrine-refractory population, the values were 
39.2 months (95% CI, 30.2 to 50.0) and 35.1 
months (95% CI, 26.8 to 50.1), respectively. In the 
endocrine-sensitive population, the hazard ratio 
for death was 0.79 (95% CI, 0.65 to 0.95), but it 
was 1.08 (95% CI, 0.65 to 1.80) in the endocrine-
refractory population (P = 0.24 for interaction). 
In patients who had received the initial diagnosis 
more than 10 years before the first metastases, 
overall survival was 65.4 months with combina-
tion therapy and 49.7 months with anastrozole 
alone (hazard ratio, 0.69; 95% CI, 0.49 to 0.98). 
However, the P value for interaction was 0.52, 
indicating that a significant differential effect of 
the intervention according to the time from di-
agnosis to metastases was not shown. The hazard 
ratio for death in the analysis of overall survival 
generally favored combination therapy in all sub-
groups, including subgroups of patients with vis-
ceral metastases, those with nonvisceral metasta-
ses, and those with metastases only in bone.
Toxic Effects
Since the initial report, no additional toxic effects 
of grade 4 or 5 have been reported in the com-
bination-therapy group. The previously reported 
toxic effects of grade 5 in this group included 
pulmonary emboli (in two patients) and a cerebro-
vascular ischemic event (in one patient). One pa-
tient in this group had grade 4 pulmonary emboli, 
and one had grade 4 neutropenia or lymphopenia. 
In the anastrozole-alone group, one additional 
patient had a grade 4 thromboembolism since the 
previous report. The previously reported grade 4 
toxic effects in this group included thrombosis or 
embolism, arthralgia, thrombocytopenia, and dys-
pnea (in one patient each).
As of the data-cutoff date for the current re-
port, toxic effects of grade 3 have occurred in 51 
of 348 patients (15%) in the combination-therapy 
group and in 43 of 338 patients (13%) in the an-
astrozole-alone group (P = 0.47). These events in-
cluded musculoskeletal pain, fatigue, hot flashes, 
mood alterations, and gastrointestinal symptoms, 
at frequencies of 1 to 4%. Few patients discon-
Figure 2. Kaplan–Meier Curves for Progression-free Survival, According to 
Trial Group.
Curves are shown for the overall trial population (Panel A) as well as for 
the subgroup of patients who had not received adjuvant endocrine therapy 
previously (Panel B).
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tinued treatment owing to adverse events or side 
effects (5 patients in the anastrozole-alone group 
and 12 in the combination-therapy group).
Discussion
In this trial, we found that combination therapy 
with anastrozole plus fulvestrant significantly pro-
longed, as compared with treatment with anastro-
zole alone, the primary and secondary end points 
of progression-free survival (P = 0.007) and long-
term overall survival (P = 0.03) when used as first-
line therapy for hormone-receptor–positive met-
astatic breast cancer in postmenopausal women. 
Furthermore, sequential therapy with anastrozole 
and fulvestrant (45% of patients crossed over to 
fulvestrant alone) did not negate the significance 
of the long-term overall survival benefit with the 
combination therapy as compared with anastro-
zole. Furthermore, this improvement was seen 
despite the use of a maintenance dose of fulves-
trant (after the first-month loading dose) that was 
lower than the now-standard higher dose (i.e., 
250 mg rather than 500 mg per month). The 
significant benefit with the combination therapy 
was observed despite longer progression-free sur-
vival and overall survival in the anastrozole-alone 
group than was projected at the start of the trial, 
with the results in the combination-therapy group 
even surpassing the projected survival in that 
group.
The absolute median prolongation in overall 
survival of 7.8 months was greater than the prolon-
gation in progression-free survival of 1.5 months 
owing to late divergence of the progression-free 
survival curves after the median and early diver-
gence of the overall survival curves before the me-
dian. However, the relative benefit with regard to 
overall survival is similar to the relative benefit 
in progression-free survival (hazard ratio for dis-
ease progression or death, 0.81; hazard ratio for 
death, 0.82). Postprogression survival was similar 
in the two groups, which reflects the finding that, 
despite crossover to fulvestrant in the anastrozole-
alone group and the multiple lines of postpro-
gression therapies typically administered in these 
patients, the progression-free survival benefit of 
up-front combination therapy resulted in pro-
longed overall survival. This additional benefit 
occurred in the absence of clinically significant 
between-group differences in the incidence of 
toxic effects of grade 3 to 5 or the discontinuation 
of treatment, even with long-term follow-up and 
despite a longer duration of combination therapy.
Variable
No. of 
Patients
No. of 
Deaths
Hazard Ratio for Death 
(95% CI) P Value
Median Overall 
Survival
Patients Alive at 
5 Yr (95% CI)
mo %
Total trial population 694 0.82 (0.69–0.98) 0.03
Anastrozole 345 261 42.0 33 (28–38)
Anastrozole plus fulvestrant 349 247 49.8 42 (37–47)
Previous endocrine therapy†
Yes 280 0.97 (0.74–1.27) —
Anastrozole 139 106 43.5 34 (26–42)
Anastrozole plus fulvestrant 141 108 48.2 38 (30–46)
No 414 0.73 (0.58–0.92) —
Anastrozole 206 155 40.3 32 (25–38)
Anastrozole plus fulvestrant 208 139 52.2 45 (38–51)
*  Shown are the stratified analyses of overall survival with combination therapy (anastrozole plus fulvestrant) as compared with anastrozole 
alone. The median overall survival, the hazard ratios for death with 95% confidence intervals, and the stratified P values (calculated by the 
log-rank test) are shown for the overall trial population and for the two indicated subgroups that were based on previous receipt or nonre-
ceipt of endocrine therapy. The percentages of patients alive at 5 years, along with 95% confidence intervals, are shown for the overall trial 
population and for the two indicated subgroups.
†  P = 0.09 for interaction in this subgroup analysis.
Table 1. Overall Survival with Anastrozole plus Fulvestrant, as Compared with Anastrozole Alone.*
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These results of our trial (S0226) are in con-
trast to the results of two similarly conducted 
prospective, randomized trials of single-agent 
aromatase inhibitors as compared with the com-
bination of an aromatase inhibitor plus fulvestrant 
(the FACT [Fulvestrant and Anastrozole Combina-
tion at First Relapse Trial] and SoFEA [Study of 
Faslodex with or without Concomitant Arimidex 
vs. Exemestane Following Progression on Non-
steroidal Aromatase Inhibitors] trials).3,4 How-
ever, important differences distinguish the S0226 
trial and these other trials. The FACT trial was 
smaller and included a more heterogeneous pop-
ulation that included both premenopausal and 
postmenopausal women as well as women with 
locally advanced and metastatic disease. Moreover, 
the requirement of first relapse for enrollment in 
the FACT trial excluded the untreated patients 
who had a first diagnosis of breast cancer with 
simultaneous metastasis and included a higher 
percentage of patients with previous exposure to 
antiestrogen therapy and thus a higher percent-
age of patients with recent exposure to antiestro-
gen therapy than were included in the current trial. 
Indeed, progression-free survival and overall sur-
vival in the FACT trial were shorter than in the 
S0226 trial. Moreover, because of chance alone, 
patients with liver metastasis who have a poor 
prognosis and patients with previous exposure to 
antiestrogen therapy were overrepresented in the 
combination-therapy group of the FACT trial. 
These factors — along with our observation that 
recent exposure to an antiestrogen, such as tamox-
ifen, predicts a lack of superiority of antiestrogen 
fulvestrant–containing therapy to therapy with an 
aromatase inhibitor alone — may explain the null 
results with combination therapy in the FACT trial. 
In support, the CONFIRM (Comparison of Faslo-
dex in Recurrent or Metastatic Breast Cancer) trial 
showed that recent exposure to adjuvant tamoxifen 
therapy was associated with survival of just 2 years, 
even with high-dose fulvestrant.5
In the case of the SoFEA trial, in which the 
addition of fulvestrant to anastrozole therapy did 
not result in better outcomes than treatment with 
exemestane alone, only patients with acquired 
endocrine resistance (who had disease progres-
sion while they were receiving an aromatase in-
hibitor) were enrolled.4 The overall survival in the 
SoFEA trial was less than 2 years, which was as 
expected in the context of acquired endocrine re-
sistance, and this survival level is much shorter 
than the overall survival in the S0226 trial (ap-
proximately 46 months). One would expect little 
benefit from any endocrine therapy in patients 
with acquired endocrine resistance.
In this regard, patients enrolled in the S0226 
trial were more similar to those in two other tri-
als, the FIRST (Fulvestrant First-Line Study Com-
paring Endocrine Treatments) and FALCON (Ful-
vestrant and Anastrozole Compared in Hormonal 
Therapy Naïve Advanced Breast Cancer) trials, in 
which patients with advanced breast cancer who 
Figure 3. Kaplan–Meier Curves for Overall Survival, According to Trial 
Group.
Curves are shown for the overall trial population (Panel A) as well as for 
the subgroup of patients who had not received adjuvant endocrine therapy 
previously (Panel B).
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had not had any previous exposure to endocrine 
therapy (77% of the patients in the FIRST trial and 
100% of those in the FALCON trial) were ran-
domly assigned to receive single-agent fulvestrant 
(at a dose of 500 mg per month) or anastrozole 
alone.6,7 Similar to the results of the S0226 trial, 
in the FIRST and FALCON trials, the benefit of 
fulvestrant therapy as compared with treatment 
with anastrozole alone was particularly compel-
ling in the population of patients who had not 
received endocrine therapy previously. In addition, 
in the S0226 trial, patients who had more than 
10 years between diagnosis and metastasis had 
the most benefit from the combination therapy 
regardless of previous tamoxifen use. Overall, the 
percentage of patients alive at 5 years was 42% 
with the combination therapy, as compared with 
33% with anastrozole therapy in the trial that in-
volved only patients with metastatic disease, and 
this result occurred despite the inclusion of some 
patients with a Zubrod’s performance-status score 
of 2, some with endocrine-refractory disease, and 
some with HER2-positive disease.
In the FALCON trial, which compared fulves-
trant with anastrozole, patients with nonvisceral 
disease had a marked prolongation in progres-
sion-free survival, but similar findings were not 
observed with fulvestrant in patients with vis-
ceral disease.7 In contrast, in the S0226 trial, the 
two subgroups had a trend toward longer pro-
gression-free survival and overall survival with 
the combination therapy than with anastrozole 
alone, and the interaction test for differential ben-
efit was not significant. The strategy of using 
anastrozole plus fulvestrant therapy may remain 
effective in the context of visceral metastasis, 
which is often an indication of a high-volume 
disease and probably multiple clones. Moreover, 
when we compare across trials, in the pure popu-
lation of patients who had never received endo-
Figure 4. Subgroup Analysis of Overall Survival.
Shown are the results of subgroup analyses of the treatment effect on overall survival. Hazard ratios for death in  
the group that received combination therapy with fulvestrant plus anastrozole, as compared with the group that  
received anastrozole alone, are shown along with 95% confidence intervals.
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crine therapy, the hazard ratio in the group receiv-
ing fulvestrant-containing therapy, as compared 
with a common control group receiving anastro-
zole, was 0.73 (in both the analyses of progres-
sion-free and overall survival) in the S0226 trial, 
as compared with 0.80 (in the analysis of pro-
gression-free survival; overall survival not yet re-
ported) in the FALCON trial.
It is also important to note from the afore-
mentioned trials and the trials of molecularly 
targeted agents such as cyclin-dependent kinase 
4 and 6 (CDK4/6) inhibitors and antiangiogenic 
agents such as bevacizumab in patients with 
hormone-receptor–positive breast cancer that pop-
ulations of patients who had not received endo-
crine therapy previously or who had endocrine-
sensitive disease represent a substantial portion 
of the populations in trials of first-line and sub-
sequent endocrine therapy.6-16 Therefore, these 
are important considerations in cross-trial com-
parisons.6-16
In conclusion, at a maximum of 12 years of 
follow-up in patients without disease progression, 
the combination of the selective estrogen-recep-
tor down-regulator fulvestrant and the aromatase 
inhibitor anastrozole, given as first-line endocrine 
therapy, resulted in superior long-term progres-
sion-free survival and overall survival, as com-
pared with anastrozole alone, among postmeno-
pausal women with hormone-receptor–positive 
metastatic breast cancer. The results suggest that 
the benefits were particularly notable in women 
who had not received endocrine therapy previously.
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